Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 996 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Dose Escalation of Placebo Clear all

Conditions: Anhedonia, Depression
Interventions: Carbidopa Levodopa, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 25 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Down Syndrome, Cognitive Dysfunction
Interventions: Aricept (donepezil hydrochloride), Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 11 Years to 17 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 2
States / cities: San Antonio, Texas • Herndon, Virginia

Conditions: Hyperbilirubinemia, Neonatal
Interventions: Stannsoporfin, Placebo, PhotoTherapy (as needed); Drug · Other
Lead sponsor: InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company; Industry
Eligibility: 1 Minute to 48 Hours
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 9
States / cities: Colton, California • San Diego, California • Honolulu, Hawaii + 5 more

Conditions: Gout, Hyperuricemia
Interventions: ABP-671, Placebo; Drug · Other
Lead sponsor: Atom Therapeutics Co., Ltd; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: CD101 IV, Placebo; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Type 2 Diabetes
Interventions: Mesenchymal Precursor Cells (MPCs); Drug
Lead sponsor: Mesoblast, Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 18
States / cities: Garden Grove, California • Miami, Florida • Orlando, Florida + 15 more

Conditions: Pre-Eclampsia
Interventions: recombinant human relaxin; Drug
Lead sponsor: Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Lexington, Kentucky • Cincinnati, Ohio

Conditions: Malaria
Interventions: BNT165c, BNT165d, Placebo; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 163 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more

Conditions: Systemic Lupus Erythematosus
Interventions: AMG 557; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 11
States / cities: Anniston, Alabama • Phoenix, Arizona • San Leandro, California + 8 more

Conditions: Tobacco Use Disorder
Interventions: ModafinilNicotine Replacement Therapy, Modafinil; Drug
Lead sponsor: Catherine Martin, MD; Other
Eligibility: 16 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Healthy Men, Male Contraception
Interventions: Placebo, 11β-methyl-nortestosterone-dodecylcarbonate; Drug
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Torrance, California • Seattle, Washington

Conditions: Chronic Kidney Disease
Interventions: LY3113593, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Orlando, Florida • Indianapolis, Indiana • Shreveport, Louisiana + 2 more

Conditions: Sickle Cell Disease
Interventions: TAK-755, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 14
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 11 more

Conditions: Spasmodic Torticollis
Interventions: Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin, Physiologic saline; Drug · Other
Lead sponsor: Mentor Worldwide, LLC; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Overweight or Obesity, Healthy
Interventions: LY4064912, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Los Alamitos, California • San Antonio, Texas

Conditions: Coronavirus (SARS-CoV)
Interventions: Aluminum hydroxide, Placebo, SARS-CoV; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Spinal Cord Injury, Autonomic Dysreflexia, Baroreceptor Integrity, Sympathetic Integrity, Vagal Integrity, Autonomic Integrity, Hypotensive, Cognitive Function, Cerebral Blood Flow, Blood Pressure
Interventions: Midodrine Hydrochloride, Pyridostigmine Bromide, Mirabegron, Placebo; Drug · Other
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: West Orange, New Jersey • The Bronx, New York

Conditions: Influenza
Interventions: VIS410, Placebo; Drug
Lead sponsor: Visterra, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Heart Failure
Interventions: BAY2413555 Dose 1, BAY2413555 Dose 2, Placebo to BAY2413555; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Atlanta, Georgia • Silver Spring, Maryland • Camp Hill, Pennsylvania

Conditions: Overweight, Obesity
Interventions: LY4167586, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Injury of Kidney, Acute Renal Failure
Interventions: I5NP (a small interfering RNA), placebo; Drug
Lead sponsor: Quark Pharmaceuticals; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Cleveland, Ohio + 3 more

Conditions: Persistent HPV16 Infection
Interventions: NWRD09, Placebo; Biological
Lead sponsor: Newish Biotech (Wuxi) Co., Ltd.; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Alcoholic Steatohepatitis (NASH)
Interventions: GR-MD-02, Placebo; Drug
Lead sponsor: Galectin Therapeutics Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteer
Interventions: Gantenerumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Orlando, Florida

Search by objective public record fields.

Dopaminergic Therapy for Anhedonia - 2

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects

A Single Ascending Dose Study of CD101 IV in Healthy Subjects

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

Evaluation of the Safety of Relaxin in Preeclampsia

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

A Study of AMG 557 in Adults With Systemic Lupus Erythematosus

Safety of Combining Modafinil and Nicotine Replacement Therapy in Treating Nicotine Dependent Adolescents

28-Day Repeat-Dose, Dose Escalation Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men

A Study of LY3113593 in Participants With Chronic Kidney Disease

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease

PurTox (Botulinum Toxin Type A) for the Treatment of Adult Onset Spasmodic Torticollis/Cervical Dystonia

A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

SARS Coronavirus Vaccine (SARS-CoV)

The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury

A Study of VIS410 to Assess Safety and Pharmacokinetics

A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT)

A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular Surgery

Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection

Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis

A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers